share_log

藥明生物：自願公告

WUXI BIO: VOLUNTARY ANNOUNCEMENT

Hong Kong Stock Exchange ·  May 17 12:00
Summary by Futu AI
藥明生物於2024年5月17日發布自願公告，回應美國眾議院監督和問責委員會就修訂版法案草案(H.R. 8333)於5月15日的會議。該法案草案刪除了與藥明生物CEO相關的內容，並增設不溯及既往的「祖父」條款，提供至2032年1月1日的過渡期。藥明生物被列為「受關注的生物技術公司」，公司表示這是未經正當程序的不合理預設性指定。藥明生物強調，公司無從事人類基因組學業務，也未收集人類基因組數據，並重申不會對美國或其他國家構成安全風險。公司將繼續關注法案進程，並承諾遵守嚴格的合規標準和法律法規。公告由董事長李革博士代表董事會發出，提醒股東及投資者買賣證券時需審慎。
藥明生物於2024年5月17日發布自願公告，回應美國眾議院監督和問責委員會就修訂版法案草案(H.R. 8333)於5月15日的會議。該法案草案刪除了與藥明生物CEO相關的內容，並增設不溯及既往的「祖父」條款，提供至2032年1月1日的過渡期。藥明生物被列為「受關注的生物技術公司」，公司表示這是未經正當程序的不合理預設性指定。藥明生物強調，公司無從事人類基因組學業務，也未收集人類基因組數據，並重申不會對美國或其他國家構成安全風險。公司將繼續關注法案進程，並承諾遵守嚴格的合規標準和法律法規。公告由董事長李革博士代表董事會發出，提醒股東及投資者買賣證券時需審慎。
Pharma Biologics issued a voluntary notice on May 17, 2024 in response to the May 15 meeting of the U.S. House Committee on Oversight and Accountability on the Amendment Bill (H.R. 8333). The bill removes content related to the CEO of pharmaceutical biologics and adds the long-standing “grandfather” clause, providing for a transition period of January 1, 2032. Pharma Biologics is listed as a “Biotechnology Company of Concern”, which the company says is an unreasonable default designation without due process. Pharmacobiology emphasized that the company does not engage in human genomics business, nor does it collect human genome data, and reiterates that it does not pose a safety risk to the United States or other countries. The company will continue to focus on the legislative process and pledge to adhere to strict compliance standards and regulations. The announcement was issued by the Chairman, Dr. Li Keung, on behalf of the Board, reminding shareholders and investors to exercise caution when buying and selling securities.
Pharma Biologics issued a voluntary notice on May 17, 2024 in response to the May 15 meeting of the U.S. House Committee on Oversight and Accountability on the Amendment Bill (H.R. 8333). The bill removes content related to the CEO of pharmaceutical biologics and adds the long-standing “grandfather” clause, providing for a transition period of January 1, 2032. Pharma Biologics is listed as a “Biotechnology Company of Concern”, which the company says is an unreasonable default designation without due process. Pharmacobiology emphasized that the company does not engage in human genomics business, nor does it collect human genome data, and reiterates that it does not pose a safety risk to the United States or other countries. The company will continue to focus on the legislative process and pledge to adhere to strict compliance standards and regulations. The announcement was issued by the Chairman, Dr. Li Keung, on behalf of the Board, reminding shareholders and investors to exercise caution when buying and selling securities.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.